Consorci Sanitari de Terrassa
Terrassa, Barcelona, 08227, Spain
NCT Number: NCT05307575
COVID-19 neurological effects can generate long-term neurobehavioral dysfunction. Our main objective is to examine the impact of COVID-19 on neurobehavior and its relationship with illness severity. Besides, we aim to study structural and functional brain connectivity in a subsample of middle-aged post-COVID-19 individuals. Finally, we aim to develop predictive models of neurobehavioural evolution in post-COVID-19 based on multimodal data.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Terrassa, Barcelona, 08227, Spain
NAUTILUS is an observational, cross-sectional, and multicenter study. It will be performed at 22 public hospitals. Two groups of COVID-19 adults (Severe N=210, Moderate-mild N=210, WHO criteria) reporting cognitive complaints will compare to healthy controls (N=210). They will be assessed on neurobehavioral status. We will perform brain MRI in a subsample (N=120, 40 per group), and we will obtain potential biomarkers of neural damage (smell function, retinal blood plexuses integrity, and inflammation). Moreover, we will use machine learning-based algorithms based on demographics, previous pathologies, lifestyle, clinical data, and biomarkers to predict neurobehavioral models.
Expected results: Identify the neurobehavioral impact of post-COVID-19 individuals and the discriminative power of multimodal biomarkers in adverse outcomes. Our result would help develop clinically useful models to predict the neurobehavioral impact to develop future personalized and preventive intervention strategies.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
PCS from SEVERE COVID-19 group
Inclusion criteria
Exclusion criteria
PCS from MILD COVID-19 group
Exclusion criteria
Healthy adult CONTROL group
Inclusion criteria
Exclusion criteria
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Auditory attention is measured with Digit Span Forward. Participants are asked to repeat numbers in the same order as read aloud by the examiner. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Working memory is measured with Digit Span Backward. Participants are asked to repeat the numbers in the reverse order of that presented by the examiner. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Language is measured with the Boston Naming Test. It consists of 60 line drawings of objects of graded difficulty, ranging from very common things to less familiar objects. The total score is the sum of correct answers. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Verbal memory is measured with the Auditory Verbal Learning Test (AVLT). It is a word-learning test where five presentations of a 15-word list are given, each followed by an attempted recall. This is followed by a second 15-word interference list (list B), followed by recall of list A. Delayed recall and recognition are also tested. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Visual memory is measured with the Rey-Osterrieth Complex Figure (ROCF) test. The participants are asked to copy complex geometric shapes and then reproduce them from memory. A delayed recall is also tested. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Processing speed is measured with Coding subtest of WAIS. Participants are asked to use a key to put in the appropriate symbols for a list of numbers. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Perceptual reasoning is measured with Matrix reasoning subtest of WAIS. Participants are asked to choose which of some possible options the missing picture is from matrix of abstract pictures. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
A composite score is made with the z-scores of phonemic (sum of the three letters) and semantic fluency, Trail Making Test B (time) and STROOP test (color-word interference total items in 120 seconds).
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Social cognition is measured with the Reading the Mind in the Eyes Test. Participants are asked to choose the emotional state that best describes the eyes, choosing between one of four possible emotions in the 36 photographs of male and female eyes depicting emotional states. Higher scores mean a better outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Anxiety is measured with the 7-item Generalized Anxiety Disorder Scale (GAD-7), a Likert-type scale with questions ranging from "not at all" (0 points) to "nearly every day" (3 points). The maximum score is 24. Higher scores mean a worse outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Depression is measured with the Patient Health Questionnaire-9 (PHQ-9) which scores each of the 9 DSM-IV criteria as "not at all" (0 points) to "nearly every day" (3 points). Higher scores mean a worse outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Post-Traumatic Stress Disorder is measured with The Post-Traumatic Stress Disorder Checklist (PCL-5), a 20-item questionnaire corresponding to the DSM-5 symptom criteria for PTSD, which scores each criterion as "not at all" (0 points) to "extremely" (4 points). The ratings of items are added together to calculate the total score (range=0-80). Higher scores mean a worse outcome.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Fatigue is measured with the Chalder Fatigue Scale, an 11-item questionnaire measuring the severity of physical and mental fatigue on two separate subscales. Seven items represent physical fatigue (items 1-7) and 4 represent mental fatigue (items 8-11). Each item " less than usual" (0) to " much more than usual" (3). The ratings of items are added together to calculate the total score (range=0-33). High scores represent high levels of fatigue.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Quality of life is measured with a 12-item World Health Organization Disability Assessment Schedule-II (WHODAS-II). Patients are asked to state the level of difficulty experienced, considering how they usually do the activity. The scale scores each item as "none" (1) to "cannot do" (5). The total score is calculated with an SPSS syntax, and the range varies from 0 to 100, with higher scores reflecting more significant disability.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
White matter integrity: tractography measured by MRI
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Grey and white matter volume measured by MRI
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Resting state brain activity using fMRI
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of IL-6 are measured with enzyme-linked immunosorbent assay (ELISA) Kit
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of NGF are measured with ELISA Kit
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of GFAp are measured with ELISA Kit
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of malondialdehyde are measured with TBARS assay method
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of Ferritin are measured with biochemical assay
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
The plasma levels of CRP are measured with high sensitivity c-reactive protein ELISA Kit
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Smell function is evaluated with the University of Pennsylvania Smell Identification Test (UPSIT), which measures the individual's ability to detect odors at a suprathreshold level. The UPSIT comprises four booklets, each of which contains ten pages. An odorized "scratch & sniff" label is present on each booklet page. The subject scratches the label and then indicates which of the four response alternatives best matches the perceived smell. A score ranging from 6-18 means anosmia, 19-25 means severe microsmia, 26-30 in women and 26-29 in men means moderate microsmia, 31-34 in women and 30-33 in men means mild microsmia and a score of more than 34 in women and 33 in men means normosmia.
Time frame: At the time of inclusion of the participant, between 3 and 12 months from the start of COVID-19
Retinal plexuses integrity is measured with Optical Coherence Tomography Angiography (OCTA)
Consorci Sanitari de Terrassa
Other
Cognition, Emotion/Behavior, Functionality and Brain Connectivity in Recovered COVID-19 Patients
Acronym: NAUTILUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05846126
Behavior, COVID-19
Terrassa, Spain
View Trial DetailsNCT05841498
COVID-19, Chronic Disease
Mainz, Rhineland-Palatinate, Germany
View Trial DetailsNCT05682560
COVID-19, Chronic Disease
Miami Lakes, Florida, United States
View Trial DetailsNCT05638620
Autonomic Nervous System Diseases, Basal Ganglia Diseases
New York, United States
View Trial Details